This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline
by Zacks Equity Research
IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients
by Zacks Equity Research
Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.
LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Forget Zimmer Biomet (ZBH), Buy These 3 Medical Devices Stocks
by Urmimala Biswas
With orthopedic stocks like Zimmer Biomet (ZBH) are grappling with several issues, it is wise to invest in medical device stocks like TMO, NEOG and CERN instead for 2022.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
by Zacks Equity Research
BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm
by Zacks Equity Research
Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.
Thermo Fisher (TMO) Releases New Update for Omicron Detection
by Zacks Equity Research
Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.
Hologic (HOLX) to Meet High Testing Demand With Panther Trax
by Zacks Equity Research
Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $650.70, moving -0.15% from the previous trading session.
Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM
by Zacks Equity Research
CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.
BD's (BDX) Latest Buyout to Enhance its Digital Capabilities
by Zacks Equity Research
BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $651.70, marking a +0.99% move from the previous day.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.
Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.